Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor’s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Company profile
Ticker
RCOR, RCOR-WT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Chardan Healthcare Acquisition 2 Corp., Chardan Healthcare Acquisition III Corp.
SEC CIK
Corporate docs
Subsidiaries
Renovacor Holdings, Inc. ...
RCOR stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
12 Dec 22
EFFECT
Notice of effectiveness
6 Dec 22
EFFECT
Notice of effectiveness
6 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Dec 22
POS AM
Prospectus update (post-effective amendment)
1 Dec 22
POS AM
Prospectus update (post-effective amendment)
1 Dec 22
8-K
Completion of Acquisition or Disposition of Assets
1 Dec 22
25-NSE
Exchange delisting
1 Dec 22
424B3
Prospectus supplement
10 Nov 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 53.71 mm | 53.71 mm | 53.71 mm | 53.71 mm | 53.71 mm | 53.71 mm |
Cash burn (monthly) | 2.76 mm | 2.63 mm | 4.04 mm | 3.17 mm | 2.56 mm | 2.50 mm |
Cash used (since last report) | 52.14 mm | 49.72 mm | 76.22 mm | 59.94 mm | 48.41 mm | 47.19 mm |
Cash remaining | 1.58 mm | 3.99 mm | -22.51 mm | -6.22 mm | 5.30 mm | 6.52 mm |
Runway (months of cash) | 0.6 | 1.5 | -5.6 | -2.0 | 2.1 | 2.6 |
Institutional ownership, Q4 2022
10.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 37 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.17 bn |
Total shares | 1.89 mm |
Total puts | 0.00 |
Total calls | 203.32 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Broadview Ventures I | 974.53 k | $8.20 mm |
Oliveira Steven Michael | 575.00 k | $4.73 mm |
Clear Street | 279.94 k | $0.00 |
Radcliffe Capital Management | 58.88 k | $1.15 bn |
Sandia Investment Management | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Dec 22 | Magdalene Cook | Common Stock | Sale back to company | Dispose D | No | No | 0 | 147,083 | 0.00 | 0 |
1 Dec 22 | Magdalene Cook | Common Stock | Grant | Acquire A | No | No | 0 | 147,083 | 0.00 | 147,083 |
1 Dec 22 | Magdalene Cook | Common Stock | Sale back to company | Dispose D | No | No | 0 | 70,825 | 0.00 | 0 |
1 Dec 22 | Magdalene Cook | Common Stock | Sale back to company | Dispose D | No | No | 0 | 451,448 | 0.00 | 70,825 |
1 Dec 22 | Magdalene Cook | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0 | 141,625 | 0.00 | 0 |
1 Dec 22 | Magdalene Cook | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0 | 238,793 | 0.00 | 0 |
1 Dec 22 | Marc Semigran | Common Stock | Sale back to company | Dispose D | No | No | 0 | 35,226 | 0.00 | 0 |
1 Dec 22 | Marc Semigran | Common Stock | Grant | Acquire A | No | No | 0 | 35,226 | 0.00 | 35,226 |
1 Dec 22 | Marc Semigran | Common Stock | Sale back to company | Dispose D | No | No | 0 | 17,425 | 0.00 | 0 |
1 Dec 22 | Marc Semigran | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0 | 34,850 | 0.00 | 0 |